AstraZeneca: U.S. Vaccine Trial Shows Efficacy in All Age Groups, No Increased Risk of Blood Clots

The study did not find evidence of increased risk of blood clots, a concern that led several European nations to suspend the use of the vaccine last week. Many reinstated the vaccine after the European Medicines Agency reported that the vaccine is safe and effective. The vaccine, which proved 79% effective against preventing symptomatic COVID-19 and 100% effective against stopping severe disease and hospitalizations, is likely to be approved for use in the U.S. in April.
Read more...

;